• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Garadacimab significantly reduces frequency of hereditary angioedema exacerbations

byJessie WillisandTeddy Guo
March 16, 2022
in Chronic Disease, Hematology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Garadacimab significantly reduced the number of monthly attacks in patients with hereditary angioedema compared to placebo.

2. No serious adverse events were observed in the treatment group with garadacimab.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Although relatively rare, hereditary angioedema is a debilitating disorder that leads to recurrent attacks of severe swelling in various parts of the body. A new potential prophylactic treatment for angioedema attacks is garadacimab, a monoclonal IgG antibody targeting activated FXII. In this randomized controlled trial, 32 patients were assigned to receive either placebo or 75 mg, 200 mg, or 600 mg of subcutaneous garadacimab. In a 12-week treatment period, the number of monthly attacks was greatly reduced in the garadacimab group compared to placebo with a 100% reduction in the 200 mg treatment group. Of note, garadacimab was well-tolerated with no serious adverse events. Limitations of this study include the small sample size, likely given the rareness of the disorder. Nonetheless, this study provides a potential option for prophylactic management of hereditary angioedema attacks.

Click to read the study in the Lancet

Relevant Reading: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update

RELATED REPORTS

Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks

#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema

#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks

In-Depth [randomized controlled trial]: This phase 2 trial took place across 12 research centers in four countries (Canada, Germany, Israel, and the USA). Inclusion criteria included patients with hereditary angioedema (HAE-C1-INH) aged 18-65 years. Patients enrolled were randomized 1:1:1:1 to either placebo, 75 mg, 200 mg, or 600 mg of subcutaneous garadacimab. The primary measured outcome was number of attacks per month experienced by patients. A total of 32 patients were randomized with a median age of 39.5 years with 56% female. During the 12-week treatment period, the rate of attacks was significantly reduced in the garadacimab groups compared to placebo. The median number of attacks was 4.6 in the placebo group, 0.0 with 75 mg, 0.0 with 200 mg, and 0.3 with 600 mg garadacimab. This translated to a 93% reduction in the 600 mg group (p=0.0003) and a 100% reduction in the 200 mg group (p=0.0002). There were no serious adverse events in either group, including no events of anaphylaxis, VTE, or bleeding.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: angioedemabradykininC1-inhibitor deficiencyEdemaGaradacimabhereditary angioedema
Previous Post

Low- and no-calorie sweetened beverages associated with reduced body weight compared to sugar-sweetened beverages: a systematic review and meta-analysis

Next Post

Wellness Check: Addictions

RelatedReports

Pharma

Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks

November 25, 2024
#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema
StudyGraphics

#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema

August 13, 2024
#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks
StudyGraphics

#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks

July 31, 2024
Chronic Disease

Oral sebetralstat provides early symptom relief for hereditary angioedema attacks

July 15, 2024
Next Post
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

Wellness Check: Addictions

Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer

Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ

Breast cancer overdiagnosis rates not as high as estimated previously

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vaporized nicotine products may be effective for smoking cessation among people with social disadvantage
  • #VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis
  • 2 Minute Medicine Rewind July 14, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.